Revance Therapeutics Inc (NASDAQ:RVNC) CEO L Daniel Browne sold 6,452 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $31.64, for a total transaction of $204,141.28. Following the completion of the transaction, the chief executive officer now owns 130,208 shares in the company, valued at approximately $4,119,781.12. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

L Daniel Browne also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Wednesday, March 7th, L Daniel Browne sold 27,283 shares of Revance Therapeutics stock. The shares were sold at an average price of $31.43, for a total transaction of $857,504.69.

Shares of Revance Therapeutics Inc (NASDAQ:RVNC) traded down $0.65 on Friday, hitting $31.00. 965,901 shares of the stock traded hands, compared to its average volume of 382,940. Revance Therapeutics Inc has a 52 week low of $18.42 and a 52 week high of $37.45. The firm has a market cap of $1,161.07, a price-to-earnings ratio of -7.77 and a beta of 1.36.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by ($0.15). Revance Therapeutics had a negative return on equity of 64.40% and a negative net margin of 46,025.57%. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.09 million. During the same quarter last year, the company earned ($0.95) EPS. The business’s revenue for the quarter was down 50.7% compared to the same quarter last year. equities research analysts forecast that Revance Therapeutics Inc will post -3.64 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in RVNC. Alliancebernstein L.P. increased its stake in shares of Revance Therapeutics by 4,063.7% during the 4th quarter. Alliancebernstein L.P. now owns 907,695 shares of the biopharmaceutical company’s stock worth $32,450,000 after purchasing an additional 885,895 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Revance Therapeutics by 127.1% during the 4th quarter. Jennison Associates LLC now owns 857,536 shares of the biopharmaceutical company’s stock worth $30,657,000 after purchasing an additional 480,008 shares during the last quarter. Perceptive Advisors LLC acquired a new position in shares of Revance Therapeutics during the 4th quarter worth $14,300,000. Senzar Asset Management LLC acquired a new position in shares of Revance Therapeutics during the 4th quarter worth $8,450,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Revance Therapeutics by 6.7% during the 4th quarter. Bank of New York Mellon Corp now owns 2,144,669 shares of the biopharmaceutical company’s stock worth $76,672,000 after purchasing an additional 135,356 shares during the last quarter. Institutional investors own 95.14% of the company’s stock.

Several research firms have weighed in on RVNC. Cantor Fitzgerald set a $50.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Wednesday, December 13th. Piper Jaffray Companies set a $48.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Thursday, March 1st. Zacks Investment Research upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Barclays began coverage on shares of Revance Therapeutics in a research note on Monday, November 27th. They issued an “overweight” rating and a $31.00 price objective on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Revance Therapeutics in a research note on Thursday, March 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the stock. Revance Therapeutics presently has an average rating of “Buy” and an average price target of $45.45.

COPYRIGHT VIOLATION WARNING: “Revance Therapeutics Inc (RVNC) CEO L Daniel Browne Sells 6,452 Shares of Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/revance-therapeutics-inc-rvnc-ceo-l-daniel-browne-sells-6452-shares-of-stock/1940723.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Insider Buying and Selling by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.